WUXI XDC (02268) saw its shares rise over 8% during the trading session. At the time of writing, the stock was up 7.54%, trading at HK$62.75, with a turnover of HK$301 million.

The company had previously issued a positive profit alert for its 2025 performance. Bank of Communications International indicated that, based on the profit alert, it has slightly revised down its 2025-2027 revenue and adjusted net profit forecasts by 1-3% to RMB 5.88 billion / 8.28 billion / 11.11 billion and RMB 1.60 billion / 2.45 billion / 3.42 billion, respectively. This represents a compound annual growth rate (CAGR) of 38%/46% for 2025-2027. The strong growth is primarily attributed to the rapid increase in comprehensive CMC orders, especially the growing contribution from late-stage clinical and commercial-phase orders.

Bank of Communications International noted that, according to statistics, there were 25 investment and financing events in the global XDC field in the first two months of 2026, a significant increase compared to 18 events in the same period of 2025. Business development transactions for XDC candidate drugs showed a similar trend, with the number of deals remaining stable while the total upfront payments increased substantially. Since the beginning of 2024, the number of investment and financing events, the number of BD transactions, and the total upfront payments in the XDC sector have shown a gradual upward trend. The continued activity in investment, financing, and BD transactions is expected to further drive improvements in downstream demand for the XDC CRDMO industry. As a leading enterprise with strong technological capabilities and an integrated delivery platform, WUXI XDC is well-positioned to continue benefiting from this important trend and expand its market share.